Dialkanoyloxybenzylidene dialkanoate

Abstract

Disclosed herein are dialkanoyloxybenzylidene dialkanoate represented by the formula, ##STR1## wherein X.sup.1 and X.sup.2 represent respectively alkanoyloxy group and a pharmaceutical composition in dosage unit form which comprises a dosage effective for the treatment of inflammatory disease of the dialkanoyloxybenzylidene dialkanoate as an active ingredient thereof.

Description

BACKGROUND OF THE INVENTION

The present invention relates to a novel dialkanoyloxybenzeylidene dialkanoate represented by the formula (I): ##STR2## wherein X.sup.1 and X.sup.2 represent respectively alkanoyloxy group, and a pharmaceutical composition in dosage unit form which comprises a dosage effective for the treatment of inflammatory disease of a compound represented by the formula (I) and a pharmaceutially acceptable carrier.

Dihydroxybenzaldehyde has recently attracted attention as an antitumour agent (refer to Japanese Patent Application Laying-Open No. 55-51018 (1980)) and as an anti-inflammatory agent (refer to Japanese Patent Application Laying-Open No. 58-83619 (1983)).

However, although dihydroxybenzaldehyde shows an excellent pharmacological activity in suppressing platelet aggregation and migration of leukocytes at a relatively low concentration in vitro, owing to the rapid metabolism thereof in the living body, it is necessary to administer a large amount thereof for a long time period for obtaining the effective effects of such pharmacological activity in vivo, and there are difficulties in administering thereof due to the stimulus action and the oxidizability of the aldehyde moiety thereof.

As a result of the present inventors' studies for developing a pharmaceutical agent which exhibits an effective pharmacological activity when administered to a living body even at a small dose rate while scarcely showing side effects, the present inventors have found the compound synthesized by the reaction, for instance, between a dihydroxybenzaldehyde and an alkanoic acid anhydride, which is represented by the formula (I): ##STR3## wherein X.sup.1 and X.sup.2 represent respectively alkanoyloxy group, and exhibits an effective pharmacological activity while scarcely showing side effects.

In the formula (I), the two X.sup.1 may occupy any of the following positions in the benzene ring thereof.

(2,3), (2,4), (2,5), (2,6), (3,4) and (3,5).

The alkyl group of the alkanoyloxy group represented by X.sup.1 and X.sup.2, respectively is a straight-chain or branched-chain alkyl group of from 1 to 18 carbon atoms, and X.sup.1 and X.sup.2 are independently represented by the formulae, ##STR4## respectively.

SUMMARY OF THE INVENTION

In a first aspect of the present invention, there is provided a dialkanoyloxybenzylidene dialkanoate represented by the formula (I): ##STR5## wherein X.sup.1 and X.sup.2 represent respectively the same or different alkanoyloxy group.

In a second aspect of the present invention, there is provided a process for producing a dialkanoyloxybenzylidene dialkanoate represented by the formula (I): ##STR6## wherein X.sup.1 and X.sup.2 represent respectively alkanoyloxy group, which comprises reacting a dihydroxybenzaldehyde with an alkanoic acid anhydride.

In a third aspect of the present invention, there is provided a pharmaceutical composition in dosage unit form which comprises a dosage effective for the treatment of inflammatory disease of a dialkanoyloxybenzylidene dialkanoate represented by the formula (I): ##STR7## wherein X.sup.1 and X.sup.2 represent respectively the same or different alkanoyloxy group and a pharmaceutically acceptable carrier.

In a fourth aspect of the present invention, there is provided a method for the treatment of inflammatory disease, which comprises administering to a patient suffering therefrom a pharmaceutically effective amount of a dialkanoyloxybenzylidene dialkanoate represented by the formula (I): ##STR8## wherein X.sup.1 and X.sup.2 represent respectively alkanoyloxy group.

BRIEF EXPLANATION OF DRAWINGS

Of the attached drawing, FIGS. 1, 3, 5 and 7 to 19 are the infrared absorption spectra of the present substances Nos. 1, 2, 3 and 4 to 16 according to the present invention, respectively, and FIGS. 2, 4 and 6 are the nuclear magnetic resonance spectra of the present substances Nos. 1, 2 and 3, respectively.

DETAILED DESCRIPTION OF THE INVENTION

The novel dialkanoyloxybenzylidene dialkanoate represented by the formula (I) according to the present invention (hereinafter referred to as the present substance), the process for producing thereof and the pharmacological composition having an anti-inflammatory activity comprising the present substance or containing the present substance as the active ingredient thereof are explained as follows.

Although the present substance can be synthesized by reacting an alkanoic acid anhydride with a dihydroxybenzaldehyde while heating a mixture of the two reactants in the presence of a strong alkali such as potassium hydroxide, sodium hydroxide and sodium acetate, the present substance can be profitably synthesized in a high yield when the alkanoic acid anhydride(III) is reacted with a dihydroxybenzaldehyde(II) in the presence of a strong acid such as sulfuric acid, hydrochloric acid and nitric acid, as is shown by the following reaction formula.

(1) In the case where X.sup.1 and X.sup.2 are the same. ##STR9## wherein the formula (I') represents the present substance in which X.sup.1 and X.sup.2 are the same and represented by ##STR10## wherein m is an integer of 1 to 18.

Namely, to one mole of 2,3-; 2,4-; 2,5-; 2,6-; 3,4- or 3,5-dihydroxybenzaldehyde represented by the formula(II), more than 3 moles of the alkanoic acid anhydride represented by the formula (III) wherein m is an integer of from 1 to 18 are added, and after melting the anhydride at a temperature higher than the melting point of the anhydride and in a range of from room temperature to 100.degree. C., a catalytic amount of a strong acid such as concentrated sulfuric acid, hydrochloric acid and nitric acid is rapidly added to the mixture while stirring thereof. Then, the reaction exothermically proceeds to obtain a homogeneous reaction mixture as a solution. The reaction completes within a time period of from one min to 5 hours, preferably from 2 min to one hour.

(2) In the case where X.sup.1 and X.sup.2 are different from each other, for instance, X.sup.1 represents ##STR11## wherein n is an integer of 1 to 18, X.sup.2 represents ##STR12## and n.noteq.m, a derivative represented by the formula: ##STR13## is reacted with an alkanoic acid anhydride represented by the formula: (C.sub.m H.sub.2m+1 CO).sub.2 O. ##STR14##

From the thus obtained reaction mixture, the present substance represented by the formula (I') can be isolated by one of known methods such as recrystallization, extraction and removal of the by-produced alkanoic acid by extraction, evaporation of the un-reacted anhydride of the alkanoic acid or column-chromatography.

The above-mentioned synthetic process only shows one embodiment for obtaining the present substance and accordingly, the process for production of the present substance should not be limited to the above-mentioned process.

Each of the present substances showed an activity of suppressing the migration of leukocytes, an activity of inhibiting the proliferation of granuloma and an activity of suppressing adjuvant arthritis as the results of in vivo tests. In addition, each of the present substances is less toxic than the known substances such as dihydroxybenzaldehyde and is effective at a smaller dose rate than that of the known substances such as dihydroxybenzaldehyde. Accordingly, each of the present substances has a pharmacological activity as an anti-inflammatory agent.

Namely, it is an ordinary anti-inflammatory agent, an anti-rheumatic agent against chronic arthritic rheumatism and an agent for treating auto-immune diseases such as glomerular nephritis and systemic erythematodes.

The mammalian toxicity and pharmacological properties of the present substances are explained as follows by the following representative compounds of the present substances. The other compounds are also useful as the anti-inflammatory agent although some difference are seen among the activities thereof.

3,4-diacetoxybenzylidene diacetate, hereinafter referred to as the present substance No. 1,

2,3-diacetoxybenzylidene diacetate, hereinafter referred to as the present substance No. 2,

2,5-diacetoxybenzylidene diacetate, hereinafter referred to as the present substance No. 3,

3,4-dipropionyloxybenzylidene dipropionate, hereinafter referred to as the present substance No. 4,

3,4-di-n-dodecanoyloxybenzylidene di-n-dodecanoate, hereinafter referred to as the present substance No. 5,

3,4-di-n-octadecanoyloxybenzylidene di-n-octadecanoate, hereinafter referred to as the present substance No. 8 and

2,5-di-n-octadecanoyloxybenzylidene di-n-octadecanoate, hereinafter referred to as the present substance No. 10.

(1) Acute mammalian toxicity

After dispersing each of the present substances Nos. 1, 4, 5, 8 and 10 in an aqueous 0.2% solution of carboxymethylcellulose, the aqueous dispersion was orally administered to each of male Jcl-ICR mice. As a result, LD.sub.50 (acute, oral) of each of the tested substances was larger than 4,000 mg/kg. LD.sub.50 (acute, oral) of the present substances Nos. 2 and 3 to male Jcl-ICR mice was larger than 2,000 mg/kg.

On the other hand, LD.sub.50 (acute, oral) of 3,4-dihydroxybenzaldehyde to male Jcl-ICR mice was 1503 mg/kg and accordingly, at least the above-mentioned present substances were found to be extremely low in acute mammalian toxicity.

(2) Activity in suppressing the migration of leukocytes:

While using groups of male Donryu rats (six rats per group) and following the carboxymethylcellulose-pouch method (refer to Ishikawa et al. YAKUGAKU ZASSHI (Journal of the Pharmaceutical Society of Japan), 88, 1472, 1968), the extent of inhibition of migration of polymorphonuclear leuckocytes to the site of inflammation by the present substance was examined. The specimen (the present substance) was dispersed in an aqueous 0.2% solution of carboxymethylcellulose and the dispersion was administered to each rat at a predetermined dose rate, and only the aqueous 0.2% solution of carboxymethylcellulose was administered to each rat of control group. Test was carried out by injecting the aqueous 0.2% solution of carboxymethylcellulose into the pouch formed in the body of the rat and after 6 hours of the injection, the number of polymorphonuclear leukocytes in the exudate into the pouch was counted. The results are shown in Table 1, and as are seen in Table 1, it was confirmed that the present substance significantly suppressed the migration of polymorphonuclear leukocytes (PMN) to the site of inflammation.

TABLE 1______________________________________ Rate ofGroup of Dose Number of suppressiontest rate PMN in exudate.sup.(1) of migrationanimals (mg/kg) (mean .+-. SE) of PMN (%)______________________________________Control -- 10.2 .+-. 0.64 --Group admin- 5 6.0 .+-. 1.00** 41.2istered with 10 5.3 .+-. 0.47*** 48.0Present Sub- 50 4.9 .+-. 0.48*** 51.9stance No. 1Control -- 10.92 .+-. 0.81 --Present Sub- 50 5.08 .+-. 0.28*** 53.5stance No. 4Present Sub- 50 4.85 .+-. 0.43*** 55.6stance No. 5Present Sub- 50 4.76 .+-. 0.54*** 56.4stance No. 8Present sub- 50 6.23 .+-. 0.15*** 42.9stance No. 10Administered with 5 6.83 .+-. 0.27*** 37.5PrednisoloneAdministered with 5 7.02 .+-. 0.64** 35.7IndomethacinAdministered with 50 7.92 .+-. 0.36* 27.53,4-dihydroxy-benzaldehyde______________________________________ Notes: .sup.(1) (number of PMN/mm.sup.3 of the exudate) .times. 10 *P < 0.05 **P < 0.01 ***P < 0.005

(3) Activity in suppressing the proliferation of granuloma:

While using groups of male Donryu rats in the fifth week after birth (5 rats per group), the activity of the present substance in suppressing the proliferation of granuloma was tested by the method of Fujimura (refer to OYOYAKURI (Pharmacometrics), 19 (3), 329, 1980).

After soaking sheets of filter paper of 13 mm in diameter and 28 mg in weight into an aqueous 2% solution of carboxymethylcellulose containing both dihydroxystreptomycin and penicillin, each of 10.sup.6 unit at the respective concentration of 0.1 mg/ml, each of the thus treated sheets was buried subcutaneously into the back of each rat under anesthesia by ether. Each specimen (the present substances) to be tested was dispersed in an aqueous 0.3% solution of carboxymethylcellulose and the dispersion was administered orally to the thus treated rat after the rat had been awaken from the anesthesia once a day for 10 days. After 10 days of the treatment, granuloma formed in the rat was removed, dried for 24 hours at 70.degree. C. and weighed. To the rats of control group, only the aqueous 0.3% solution of carboxymethylcellulose was orally administered once a day for 10 days, both results being shown in Table 2.

As are seen in Table 2, each of the tested present substances significantly suppressed the proliferation of granulating tissue formed.

TABLE 2______________________________________ GranulomaGroup of Dose Dried Rate oftest rate weight.sup.(1) suppressionanimals (mg/kg/day) (mg) (%)______________________________________Control -- 88.1 .+-. 5.0 --Present Sub- 5 50.4 .+-. 8.4** 42.8stance No. 1 10 39.4 .+-. 3.0*** 55.3 50 34.0 .+-. 4.2*** 61.4Control -- 109.4 .+-. 7.5Present Sub- 50 42.4 .+-. 5.7*** 61.2stance No. 4Present Sub- 50 39.1 .+-. 3.4*** 64.7stance No. 5Present Sub- 50 36.2 .+-. 2.6*** 66.9stance No. 8Present Sub- 50 57.0 .+-. 6.7*** 47.9stance No. 10Administered with 3 66.3 .+-. 8.4** 39.4IndomethacinAdministered with 3 63.2 .+-. 8.6** 42.2PrednisoloneAdministered with 50 70.5 .+-. 9.7* 35.63,4-dihydroxy-benzaldehyde______________________________________ Notes: .sup.(1) mean value .+-. standard error *P < 0.05 **P < 0.01 ***P < 0.005

(4) Activity in suppressing adjuvant arthritis:

While using groups of female Jcl-SD rats in the 8th week after birth (6 rats per group), the activity of the present substance in suppressing the adjuvant arthritis was tested by the method of Fujihira et al. (refer to OYOYAKURI (Pharmacometrics), 5(2), 169, 1971).

Namely, Freund's complete adjuvant was implanted to the tail of each rat under anesthesia by ether in an amount of 0.6 mg dissolved in 0.1 ml of mineral oil, and after 2 weeks of the implantation, each specimen (the present substances) to be tested was orally administered once a day for 20 days, and the state of the rat was observed.

As the results of the above-mentioned test, each of the present substances tested, namely, Nos. 1, 2, 3, 4, 5, 8 and 10 showed an excellent treating effect on the adjuvant arthritis caused by the implanted Freund's complete adjuvant. On the other hand, in the rats administered with prednisolone, the increase of the body weight was significantly suppressed, and on the autopsy thereof, a significant atrophy of the thymus thereof was observed. In the rats administered with each of the present substance, suppression of increase of body weight and atrophy of the thymus were not observed. The findings confirm that the present substance has scarcely the side effects.

Accordingly, the present substance is effective as an agent for treating chronic inflammatory diseases such as rheumatism, etc.

As are seen in the above-mentioned test results, it can be recognized that the present substance has the excellent activities in suppressing the proliferation of granuloma, in suppressing the adjuvant arthritis and in suppressing the migration of leukocytes and is extremely low in acute mammalian toxicity.

Accordingly, the present substance can be used in the extremely important uses as an anti-inflammatory agent, an anti-chronic arthritic rheumatism and an agent for treating autoimmune diseases such as systemic erythematodes and glomerular nephritis.

The present substance is possibly administered orally, intraintestinally or in the form of injection in one of the various forms of pharmaceutical formulation (so-called pharmaceutical composition) after being combined with pharmaceutically acceptable carrier(s) and/or adjuvant(s). More than two of the present substances may be used in combination or after being mixed together, and the present substance may be used after being combined with any other active ingredient for pharmaceutical use.

Since the present substance can be administered orally and parenterally, it can take any optional form of pharmaceutical compositions suitable for the route of administration. In addition, the present substance may be offered in the unit dose form, and as far as the pharmaceutical composition contains an effective amount of the present substance, the composition can take the various forms such as powder, granule, tablet, sugar-coated tablet, capsule, suppository, suspension, solution, emulsion, ampoule and injection.

Accordingly, it should be recognized that the pharmaceutical composition comprising the present substance can be formulated by application of any known means for formulation of a pharmacologically active agent.

In addition, the content of the present substance as an active ingredient in the above-mentioned pharmaceutical composition can be adjusted in a broad range of from 0.01 to 100% by weight, preferably in a range of from 0.1 to 70% by weight.

As has been stated, although the pharmaceutical composition comprising the present substance is orally or parenterally administered to human or mammals, the oral administration including sublingual administration is particularly preferable.

The parenteral administration includes subcutaneous-, intramuscular- and intravenous injection and instillation.

Since the dose rate of the present substance depends on the species, the sex, the age, the individual difference and the state of the disease of the patient to be administered therewith, there may be cases where an amount outside the following range is administered, however, in the cases where human being is the object of administration, the oral daily dose rate of one of the present substances is in a range of from 0.1 to 500 mg/kg body weight, preferably in a range of from 0.5 to 200 mg/kg body weight, more preferably in the range of from 3 to 100 mg/kg body weight, and the parenteral daily dose rate is in a range of from 0.01 to 200 mg/kg body weight, preferably in a range of from 0.1 to 100 mg/kg body weight, more preferably in the range of from 1.5 to 50 mg/kg body weight. The above-mentioned daily amount is divided equally into 1 to 4 portions, and the thus divided portion is administered at a time (one to four times per day).

The present invention will be explained more in detail while referring to the following non-limitative examples.

EXAMPLE 1

Synthesis of 3,4-diacetoxybenzylidene diacetate (the present substance No. 1)

After introducing 30 g of protocatechualdehyde(3,4-dihydroxybenzaldehyde) and 92.4 g of acetic anhydride into a 200 ml-flask and adding one drop of concentrated sulfuric acid to the content of the flask, the flask was shaken to rapidly induce a beginning of an exothermic reaction, thereby obtaining a uniform liquid reaction mixture of red in colour. After shaking the flask for 3 min, the liquid reaction mixture was poured into 500 ml of water to form a colourless, powdery crude product as a precipitate. The amount of the crude product after collecting the precipitate by filtration and drying thereof was 68.0 g (the yield: 96.6%). By subjecting the dried, crude product to recrystallization from a 2:1 mixed solvent of ethanol and ethyl acetate, 59.9 g of colourless prisms (the yield: 85.0%) were obtained as the product of the process according to the present invention, the physical properties thereof being shown as follows.

(1) Melting point: 129.0.degree. to 130.0.degree. C. (by capillary method)

(2) Elementary analytical data:

______________________________________ C (%) H (%)______________________________________Found: 55.70 4.90Calcd. as C.sub.15 H.sub.16 O.sub.8 : 55.56 4.97______________________________________

(3) Infrared absorption spectrum (by KBr-tablet method)

The spectrum is shown in FIG. 1.

(4) Nuclear magnetic resonance spectrum of .sup.1 H:

The spectrum is shown in FIG. 2 with the following peaks:

.delta. (DMSO-d.sub.6) ppm, ##STR15##

EXAMPLE 2

Synthesis of 2,3-diacetoxybenzylidene diacetate (the present substance No. 2)

In the same procedures as in Example 1 except for using 2,3-dihydroxybenzaldehyde instead of protocatechualdehyde in Example 1, the crude product of the objective substance was obtained, and by recrystallizing thereof from ethyl acetate, a colourless powdery substance was obtained as the present substance No. 2 in a yield of 78.7%. The physical properties of the product are shown as follows.

(1) Melting point: 108.5.degree. to 109.5.degree. C. (by capillary method)

(2) Elementary analytical data:

______________________________________ C (%) H (%)______________________________________Found: 55.70 4.80Calcd. as C.sub.15 H.sub.16 O.sub.8 : 55.56 4.97______________________________________

(3) Infrared absorption spectrum (by KBr-tablet method):

The spectrum is shown in FIG. 3.

(4) Nuclear magnetic resonance spectrum of .sup.1 H:

The spectrum is shown in FIG. 4 with the following peaks.

.delta.(DMSO-d.sub.6) ##STR16##

EXAMPLE 3

Synthesis of 2,5-diacetoxybenzylidene diacetate (the present substance No. 3)

In the same procedures as in Example 1 except for using 2,5-dihydroxybenzaldehyde instead of protocatechualdehyde in Example 1, the crude product of the objective substance was obtained, and by recrystallizing the crude product from ethyl acetate, colourless prisms were obtained as the product according to the present invention in a yield of 81.3%. The physical properties of the thus recrystallized product are shown as follows.

(1) Melting point: 128.5.degree. to 129.5.degree. C. (by capillary method)

(2) Elementary analytical data:

______________________________________ C (%) H (%)______________________________________Found: 55.70 4.90Calcd. as C.sub.15 H.sub.16 O.sub.8 : 55.56 4.97______________________________________

(3) Infrared absorption spectrum (by KBr-tablet method):

The spectrum is shown in FIG. 5.

(4) Nuclear magnetic resonance spectrum of .sup.1 H:

The spectrum is shown in FIG. 6 with the following peaks.

.delta.(in DMSO-d.sub.6), ppm ##STR17##

EXAMPLE 4

Synthesis of 3,4-dipropionyloxybenzylidene dipropionate (the present substance No. 4)

After introducing 20.0 g of protocatechualdehyde (3,4-dihydroxybenzaldehyde) and 76.3 g of propionic acid anhydride into a 200 ml-flask and adding one drop of concentrated sulfuric acid to the mixture in the flask, the flask was shaken to rapidly induce the beginning of an exothermic reaction, thereby obtaining a nearly uniform liquid reaction mixture of red in colour. After shaking the flask for 5 min, the liquid reaction mixture was poured into 300 g of water to obtain a crude powdery product of whitish yellow in colour. By recrystallizing the thus obtained crude product from a mixed solvent of methanol and water, 45.9 g of colourless prisms product were obtained in a yield of 83.2%, the physical properties thereof being shown as follows.

(1) Melting point: 64.0.degree. to 65.0.degree. C. (by capillary method)

(2) Elementary analytical data:

______________________________________ C (%) H (%)______________________________________Found: 60.00 6.30Calcd. as C.sub.19 H.sub.24 O.sub.8 : 59.99 6.36______________________________________

(3) Infrared absorption spectrum (by KBr-tablet method):

The spectrum is shown in FIG. 7.

(4) Nuclear magnetic resonance spectrum of .sup.1 H:

.delta. (in DMSO-d.sub.6) ppm: ##STR18##

EXAMPLE 5

Synthesis of 3,4-didodecanoyloxybenzylidene didodecanoate (the present substance No. 5)

After introducing 11.4 g of protocatechualdehyde and 127.8 g of dodecanoic acid anhydride into a 500 ml-flask, the mixture was heated to 80.degree. to 85.degree. C. to obtain a heterogeneous solution consisting of solid protocatechualdehyde and liquefied dodecanoic acid anhydride. After adding one drop of concentrated sulfuric acid to the mixture, and thus formed mixture was shaken to rapidly induce an exothermic reaction, thereby obtaining a nearly homogeneous reaction mixture of reddish brown in colour. After heating the liquid reaction mixture for 40 min at 80.degree. to 85.degree. C., a mixed solvent of 500 ml of ethanol and 50 ml of ethyl acetate was added to the reaction mixture, and the thus formed mixture was cooled to room temperature and left for while to form scaly crystals of white in colour as a precipitate. After collecting the crystals by filtration, the crystals were dried to be 56.0 g of the white scaly product in a yield of 76.7%, the physical properties of the thus obtained white scaly crystals being shown as follows.

(1) Melting point: 52.0.degree. to 53.0.degree. C. (by capillary method)

(2) Elementary analytical data:

______________________________________ C (%) H (%)______________________________________Found: 74.80 11.20Calcd. as C.sub.55 H.sub.96 O.sub.8 : 74.61 10.93______________________________________

(3) Infrared absorption spectrum (by KBr-tablet method):

The spectrum is shown in FIG. 8.

(4) Nuclear magnetic resonance spectrum of .sup.1 H:

.delta.(in DMSO-d.sub.6) ppm: ##STR19##

EXAMPLE 6

Synthesis of 3,4-di-n-tetradecanoyloxybenzylidene di-n-tetradecanoate (the present substance No. 6)

In the same procedures as in Example 5 except for using n-tetradecanoic acid anhydride instead of dodecanoic acid anhydride in Example 5, crystals were obtained, and the crystals were recrystallized from a mixed solvent (5:1) of ethanol and ethyl acetate to obtain a powdery white product in a yield of 69.7%. The physical properties of the thus obtained product are shown as follows.

(1) Melting point: 63.5.degree. to 64.5.degree. C. (by capillary method)

(2) Elementary analytical data:

______________________________________ C (%) H(%)______________________________________Found: 76.00 11.60Calcd. as C.sub.63 H.sub.112 O.sub.8 : 75.85 11.32______________________________________

(3) Infrared absorption spectrum (by KBr-tablet method):

The spectrum is shown in FIG. 9.

(4) Nuclear magnetic resonance spectrum of .sup.1 H:

.delta.(in CDCl.sub.3) ppm ##STR20##

EXAMPLE 7

Synthesis of 3,4-di-n-hexadecanoyloxybenzylidene di-n-hexadecanoate (the present substance No. 7)

In the same procedures as in Example 5 except for using n-hexadecanoic acid anhydride instead of dodecanoic acid anhydride in Example 5, crystals were obtained and by recrystallizing thereof from a mixed solvent (2:1) of ethanol and ethyl acetate, a powdery white product was obtained in a yield of 72.9%.

The physical properties of the thus obtained product are shown as follows.

(1) Melting point: 70.5.degree. to 71.5.degree. C. (by capillary method)

(2) Elementary analytical data:

______________________________________ C (%) H(%)______________________________________Found: 76.90 11.70Calcd. as C.sub.71 H.sub.128 O.sub.8 : 76.84 11.63______________________________________

(3) Infrared absorption spectrum (by KBr-tablet method)

The spectrum is shown in FIG. 10.

(4) Nuclear magnetic resonance spectrum of .sup.1 H:

.delta.(in CDCl.sub.3) ppm ##STR21##

EXAMPLE 8

Synthesis of 3,4-di-n-octadecanoyloxybenzylidene di-n-octadecanoate (the present substance No. 8)

In the same procedures as in Example 5 except for using n-octadecanoic acid anhydride instead of dodecanoic acid anhydride in Example 5, crystals were obtained, and by recrystallizing the crystals from a mixed solvent (2:1) of ethanol and ethyl acetate, a white powdery product was obtained in a yield of 73.4%. The physical properties of the thus obtained product are shown as follows.

(1) Melting point: 77.0.degree. to 78.0.degree. C. (by capillary method)

(2) Elementary analytical data:

______________________________________ C (%) H(%)______________________________________Found: 77.40 12.10Calcd. as C.sub.79 H.sub.144 O.sub.8 : 77.65 11.89______________________________________

(3) Infrared absorption spectrum (by KBr-tablet method):

The spectrum is shown in FIG. 11.

(4) Nuclear magnetic resonance spectrum of .sup.1 H:

.delta.(in CDCl.sub.3) ppm, ##STR22##

EXAMPLE 9

Synthesis of 2,5-di-n-dodecanoyloxybenzylidene di-n-dodecanoate (the present substance No. 9)

In the same procedures as in Example 5 except for using 2,5-dihydroxybenzaldehyde instead of protocatechualdehyde in Example 5, crystals were obtained, and by recrystallizing the crystals from a mixed solvent (2:1) of ethanol and ethyl acetate, a white powdery product was obtained in a yield of 76.9%. The physical properties of the thus obtained product are shown as follows.

(1) Melting point: 62.0.degree. to 63.0.degree. C. (by capillary method)

(2) Elementary analytical data:

______________________________________ C (%) H (%)______________________________________Found: 74.50 11.00Calcd. as C.sub.55 H.sub.96 O.sub.8 : 74.61 10.93______________________________________

(3) Infrared absorption spectrum (by KBr-tablet method):

The spectrum shown in FIG. 12.

(4) Nuclear magnetic resonance spectrum:

.delta. (in CDCl.sub.3) ppm, ##STR23##

EXAMPLE 10

Synthesis of 2,5-di-n-octadecanoyloxybenzylidene di-n-octadecanoate (the present substance No. 10)

In the same procedure as in Example 5 except for using 2,5-dihydroxybenzaldehyde instead of protocatechualdehyde in Example 5 and further using n-octadecanoic acid anhydride instead of dodecanoic acid anhydride in Example 5, crystals were obtained and by recrystallizing the thus obtained crystals from a mixed solvent (2:1) of ethanol and ethyl acetate, a white powdery product was obtained in a yield of 82.8%. The physical properties of the thus obtained product are shown as follows.

(1) Melting point: 84.0.degree. to 85.0.degree. C. (by capillary method)

(2) Elementary analytical data:

______________________________________ C (%) H (%)______________________________________Found: 77.40 12.00Calcd. as C.sub.79 H.sub.144 O.sub.8 : 77.65 11.89______________________________________

(3) Infrared absorption spectrum (by KBr-tablet method):

The spectrum is shown in FIG. 13.

(4) Nuclear magnetic resonance spectrum of .sup.1 H:

.delta.(in CDCl.sub.3), ppm, ##STR24##

EXAMPLE 11

Synthesis of 2,3-di-n-octadecanoyloxybenzylidene di-n-octadecanoate (the present substance No. 11)

In the same procedures as in Example 5 except for using 2,3-dihydroxybenzaldehyde instead of protocatechualdehyde in Example 5, and further using n-octadecanoic acid anhydride instead of dodecanoic acid anhydride in Example 5, crystals were obtained, and by recrystallizing the thus obtained crude crystals from a mixed solvent (5:1) of ethanol and ethyl acetate, a white powdery product was obtained in a yield of 90.0%. The physical properties of the thus obtained product, the present substance No. 11, are shown as follows.

(1) Melting point: 64.0.degree. to 65.0.degree. C. (by capillary method)

(2) Elementary analytical data:

______________________________________ C (%) H (%)______________________________________Found: 77.80 12.10Calcd. as C.sub.79 H.sub.144 O.sub.8 : 77.65 11.89______________________________________

(3) Infrared absorption spectrum (by KBr-tablet method):

The spectrum is shown in FIG. 14.

(4) Nuclear magnetic resonance spectrum of .sup.1 H:

.delta. (in CDCl.sub.3), ppm ##STR25##

EXAMPLE 12

Synthesis of 3,4-di-n-butyryloxybenzylidene di-n-butyrate (the present substance No. 12)

In a 300 ml-flask, 10 g of protocatechualdehyde and 46.3 g of butyric acid anhydride were introduced, and after adding one drop of concentrated sulfuric acid to the resultant mixture, the flask was shaken for 10 min at room temperature to obtain a liquid reaction mixture or reddish brown in colour. After adding 200 ml of ethyl acetate to the liquid reaction mixture, the system was extracted five times with each 80 ml of an aqueous 1N solution of sodium hydrogen carbonate for the removal of butyric acid contained in the liquid reaction mixture. After washing the organic layer with an aqueous saturated solution of sodium chloride, the thus washed organic layer was dried on anhydrous sodium sulfate and decolorized by treatment with activated carbon and subjected to evaporation under a reduced pressure to remove the solvent. The residue was subjected further to distillation under a reduced pressure by heating for the removal of still remaining butyric acid anhydride, thereby obtaining a pale yellow oily product in a yield of 97.4%. The physical properties of the thus obtained oily product are shown as follows.

(1) Elementary analytical data:

______________________________________ C (%) H (%)______________________________________Found: 63.10 7.40Calcd. as C.sub.23 H.sub.32 O.sub.8 : 63.29 7.39______________________________________

(2) Infrared absorption spectrum (by NaCl plate method):

The spectrum is shown in FIG. 15.

(3) Nuclear magnetic resonance spectrum

.delta.(in CDCl.sub.3), ppm, ##STR26##

EXAMPLE 13

Synthesis of 2,5-di-n-butyryloxybenzylidene di-n-butyrate (the present substance No. 13)

In the same procedures as in Example 12 except for using 2,5-dihydroxybenzaldehyde instead of protocatechualdehyde in Example 12, a pale yellow oily product, the present substance No. 13 was obtained in a yield of 97.5%. The physical properties of the product are shown as follows.

(1) Elementary analytical data:

______________________________________ C (%) H (%)______________________________________Found: 63.50 7.10Calcd. as C.sub.23 H.sub.32 O.sub.8 : 63.29 7.39______________________________________

(2) Infrared absorption spectrum (by NaCl plate method):

The spectrum is shown in FIG. 16.

(3) Nuclear magnetic resonance spectrum of .sup.1 H:

.delta. (in CDCl.sub.3), ppm, ##STR27##

EXAMPLE 14

Synthesis of 2,3-di-n-butyryloxybenzylidene di-n-butyrate (the present substance No. 14)

In the same procedures as in Example 12 except for using 2,3-dihydroxybenzaldehye instead of protocatechualdehyde in Example 12, a pale yellow oily product, the present substance No. 14, was obtained in a yield of 98.4%. The physical properties of the thus obtained oily product are shown as follows.

(1) Elementary analytical data:

______________________________________ C (%) H (%)______________________________________Found: 63.50 7.20Calcd. as C.sub.23 H.sub.32 O.sub.8 : 63.29 7.39______________________________________

(2) Infrared absorption spectrum (by NaCl plate method):

The spectrum is shown in FIG. 17.

(3) Nuclear magnetic resonance spectrum of .sup.1 H:

.delta.(in CDCl.sub.3), ppm, ##STR28##

EXAMPLE 15

Synthesis of 3,4-diacetoxybenzylidene dioctadecanoate (the present substance No. 15)

In 100 ml-flask, 11.11 g of 3,4-diacetoxybenzaldehyde and 27.55 g of stearic acid anhydride were introduced, and after heating the mixture at 80.degree. to 85.degree. C. to obtain a homogenous solution, one drop of concentrated sulfuric acid was added to the solution and the mixture was reacted at 80.degree. to 85.degree. C. for 20 min under agitation. After the reaction was over, the reaction mixture was dissolved in 150 ml of ethyl acetate while heating the reaction mixture. The white powdery crystals were separated from the reaction mixture after leaving the reaction mixture to cool, collected by filtration and dried to obtain 27.64 g of a product in a yield of 71.50%.

The thus obtained product showed the following properties.

(1) Melting point: 75.0.degree. to 76.0.degree. C. (by capillary method)

(2) Elementary Analytical Data:

______________________________________ C (%) H (%)______________________________________Found: 73.30 10.70Calcd. as C.sub.47 H.sub.86 O.sub.8 : 73.01 10.43______________________________________

(3) Infrared absorption specrum (by KBr-tablet method):

The spectrum is shown in FIG. 18.

(4) Nuclear magnetic resonance spectrum of .sup.1 H:

.delta.(in CDCl.sub.3), ppm, ##STR29##

EXAMPLE 16

Synthesis of 3,4-dioctadecanoyloxybenzylidene diacetate (the present substance No. 16)

In a 50 ml-flask, 10.2 g of 3,4-dioctadecanoylbenzaldehyde and 15.5 g of acetic anhydride were introduced, and after dissolving the 3,4-dioctadecanoylbenzaldehyde in acetic anhydride by heating the mixture to 60.degree. to 70.degree. C., one drop of concentrated sulfuric acid was added to the thus obtained solution, and the flask was shaken to initiate the reaction. A reaction exothermically proceeded to form a reaction mixture uniform and pale brown in colour. After shaking the reaction mixture for 2 min, the reaction mixture was cooled to room temperature and 100 ml of purified water were added to the reaction mixture. The thus separated white powdery crystals were collected by filtration and dried to obtain 11.73 g of a white powdery product in a yield of 99.8%. The product showed the following properties.

(1) Melting point: 81.0.degree. to 82.0.degree. C. (by capirally method)

(2) Elementary analytical data:

______________________________________ C (%) H (%)______________________________________Found: 73.00 10.60Calcd. as C.sub.47 H.sub.86 O.sub.8 : 73.01 10.43______________________________________

(3) Infrared absorption spectrum (by KBr-tablet method):

The spectrum is shown in FIG. 19.

(4) Nuclear magnetic resonance spectrum of .sup.1 H:

.delta.(in CDCl.sub.3), ppm, ##STR30##

FORMULATION EXAMPLE 1

Preparation of powdery composition and capsular composition

Ten parts by weight of 3,4-dipropionyloxybenzylidene dipropionate (the present substance No. 4), 15 parts by weight of heavy magnesium oxide and 75 parts by weight of lactose were uniformly mixed and the mixture was pulverized to obtain a powdery composition, and by capsulating the thus formed powdery composition into capsules, a capsular composition was obtained.

FORMULATION EXAMPLE 2

Preparation of granular composition

Forty-five parts by weight of 3,4-didodecanoyloxybenzylidene didodecanoate (the present substance No. 5), 15 parts by weight of starch, 16 parts by weight of lactose, 21 parts by weight of crystalline cellulose, 3 parts by weight of polyvinyl alcohol and 30 parts by weight of water were uniformly mixed, and the mixture was well kneaded.

Thereafter, the kneaded mixture was pulverized, shaped into grannular form and dried. The thus dried material was sifted to obtain a granular composition.

FORMULATION EXAMPLE 3

Preparation of an injection

Ten parts by weight of 3,4-diacetoxybenzylidene diacetate (the present substance No. 1), 3 parts by weight of benzyl alcohol and 87 parts by weight of an aqueous physiological saline solution were mixed under heating, and the thus heated uniform mixture was sterilized to obtain an injection.

Claims

1. A dialkanoyloxybenzylidene dialkanoate represented by the formula: ##STR31## wherein: X.sup.1 is a group of the formula ##STR32## X.sup.2 is a group of the formula ##STR33## and m and n are each independently an integer of from 1 to 18;

provided that the two groups X.sup.1 are not at the 3- and 5-positions of the benzene ring, simultaneously, when m and n are 1, and that the two groups X.sup.1 are not at the 3- and 4-positions of the benzene ring, simultaneously.

2. The dialkanoyloxybenzylidene dialkanoate according to claim 1, wherein both X.sup.1 and X.sup.2 represent an acetoxy group.

3. The dialkanoyloxybenzylidene dialkanoate according to claim 2, which is 2,3-diacetoxybenzylidene diacetate.

4. The dialkanoyloxybenzylidene dialkanoate according to claim 2, which is 2,5-diacetoxybenzylidene diacetate.

5. The dialkanoyloxybenzylidene dialkanoate according to claim 1 which is 2,5-di-n-dodecanoyloxybenzylidene di-n-dodecanoate.

6. The dialkanoyloxybenzylidene dialkanoate according to claim 1, which is 2,5-di-n-octadecanoyloxybenzylidene di-n-octadecanoate.

7. The dialkanoyloxybenzylidene dialkanoate according to claim 1, which is 2,3-di-n-octadecanoyloxybenzylidene di-n-octadecanoate.

8. The dialkanoyloxybenzylidene dialkanoate according to claim 1, which is 2,5-di-n-butyryloxybenzylidene di-n-butyrate.

9. The dialkanoyloxybenzylidene dialkanoate according to claim 1, which is 2,3-di-n-butyryloxybenzylidene di-n-butyrate.

10. A dialkanoyloxybenzylidene dialkanoate represented by the formula: ##STR34## wherein: X.sup.1 is a group of the formula ##STR35## X.sup.2 is a group of the formula ##STR36## and m and n are each independently an integer of from 1 to 18, provided that m is not 1 when n is 1.

11. The dialkanoyloxybenzylidene dialkanoate according to claim 10, which is 3,4-dipropionyloxybenzylidene dipropionate.

12. The dialkanoyloxybenzylidene dialkanoate according to claim 10, which is 3,4-didodecanoyloxybenzylidene didodecanoate.

13. The dialkanoyloxybenzylidene dialkanoate according to claim 10, which is 3,4-di-n-tetradecanoyloxybenzylidene di-n-tetradecanoate.

14. The dialkanoyloxybenzylidene dialkanoate according to claim 10, which is 3,4-di-n-hexadecanoyloxybenzylidene di-n-hexadecanoate.

15. The dialkanoyloxybenzylidene dialkanoate according to claim 10, which is 3,4-di-n-octadecanoyloxybenzylidene di-n-octadecanoate.

16. The dialkanoyloxybenzylidene dialkanoate according to claim 10, which is 3,4-di-n-butyryloxybenzylidene di-n-butyrate.

17. The dialkanoyloxybenzylidene dialkanoate according to claim 10, which is 3,4-diacetoxybenzylidene dioctadecanoate.

18. The dialkanoyloxybenzylidene dialkanoate according to claim 10, which is 3,4-di-octadecanoyloxybenzylidene diacetate.

19. A pharmaceutical composition in unit dosage form, which comprises:

a dosage effective for the treatment of inflammation, chronic arthritic rheumatism, systemic erythematodes or glomerular nephritis of a dialkanoyloxybenzylidene dialkanoate of the formula: ##STR37## wherein X.sup.1 is a group of the formula ##STR38## X.sup.2 is a group of the formula ##STR39## and m and n each independently is an integer of from 1 to 18, and a pharmaceutically acceptable carrier.

20. The pharmaceutical composition according to claim 19, wherein both X.sup.1 and X.sup.2 represent an acetoxy group.

21. The pharmaceutical composition according to claim 20, wherein the dialkanoyloxybenzylidene dialkanoate is 3,4-diacetoxybenzylidene diacetate.

22. The pharmaceutical composition according to claim 20, wherein the dialkanoyloxybenzylidene dialkanoate is 2,3-diacetoxybenzylidene diacetate.

23. The pharmaceutical composition according to claim 20, wherein the dialkanoyloxybenzylidene dialkanoate is 2,5-diacetoxybenzylidene diacetate.

24. The pharmaceutical composition according to claim 19, wherein the dialkanoyloxybenzylidene dialkanoate is 3,4-dipropionyloxybenzylidene dipropionate.

25. The pharmaceutical composition according to claim 19, wherein the dialkanoyloxybenzylidene dialkanoate is 3,4-didodecanoyloxybenzylidene didodecanoate.

26. The pharmaceutical composition according to claim 19, wherein the dialkanoyloxybenzylidene dialkanoate is 3,4-di-n-tetradecanoyloxybenzylidene di-n-tetradecanoate.

27. The pharmaceutical composition according to claim 19, wherein the dialkanoyloxybenzylidene dialkanoate is 3,4-di-n-hexadecanoyloxybenzylidene di-n-hexadecanoate.

28. The pharmaceutical composition according to claim 19, wherein the dialkanoyloxybenzylidene dialkanoate is 3,4-di-n-octadecanoyloxybenzylidene di-n-octadecanoate.

29. The pharmaceutical composition according to claim 19, wherein the dialkanoyloxybenzylidene dialkanoate is 2,5-di-n-dodecanoyloxybenzylidene di-n-dodecanoate.

30. The pharmaceutical composition according to claim 19, wherein the dialkanoyloxybenzylidene dialkanoate is 2,5-di-n-octadecanoyloxybenzylidene di-n-octadecanoate.

31. The pharmaceutical composition according to claim 19, wherein the dialkanoyloxybenzylidene dialkanoate is 2,3-di-n-octadecanoyloxybenzylidene di-n-octadecanoate.

32. The pharmaceutical composition according to claim 19, wherein the dialkanoyloxybenzylidene dialkanoate is 3,4-di-n-butyryloxybenzylidene di-n-butyrate.

33. The pharmaceutical composition according to claim 19, wherein the dialkanoyloxybenzylidene dialkanoate is 2,5-di-n-butyryloxybenzylidene di-n-butyrate.

34. The pharmaceutical composition according to claim 19, wherein the dialkanoyloxybenzylidene dialkanoate is 2,3-di-n-butyryloxybenzylidene di-n-butyrate.

35. The pharmaceutical composition according to claim 19, wherein the dialkanoyloxybenzylidene dialkanoate is 3,4-diacetoxybenzylidene dioctadecanoate.

36. The pharmaceutical composition according to claim 19, wherein the dialkanoyloxybenzylidene dialkanoate is 3,4-di-octadecanoyloxybenzylidene diacetate.

37. A method for the treatment of the inflammation, chronic arthritic rheumatism, systemic erythematodes or glomerular nephritis, which comprises:

administering to a patient suffering therefrom a pharmaceutically effective amount of a dialkanoyloxybenzylidene dialkanoate of the formula: ##STR40## wherein X.sup.1 is a group of the formula ##STR41## X.sup.2 is a group of the formula ##STR42## and m and n each independently is an integer of from 1 to 18.

38. The method according to claim 31, wherein both X.sup.1 and X.sup.2 represent an acetoxy group.